Lead Sponsor

Pfizer

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

No

•At least one claim for methotrexate during the variable-length pre-index period.
•At least one claim for tofacitinib or bDMARDs between 01 February 2016 and 31 July 2019 (the identification period).

•Patients with claims for other conditions for which bDMARDs are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study.
•Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with (other) bDMARDs during the one-year pre-index period.
•Patients with more than 1 bDMARD or bDMARD with tofacitinib filled on the index date will be removed from the study.